Literature DB >> 21170262

RalBP1 is necessary for metastasis of human cancer cell lines.

Zhong Wu1, Charles Owens, Nidhi Chandra, Kay Popovic, Mark Conaway, Dan Theodorescu.   

Abstract

RalA expression in human prostate cancer is associated with cell migration and is necessary for bone metastasis. However, the downstream effectors of RalA that mediate these functions remain unclear. Here we examined cell migration after small interfering RNA-mediated depletion of Ral effectors Ral binding protein 1 (RalBP1/RLIP), exocyst complex component 2 (Sec5), and phospholipase D1 (PLD1) and found that RalBP1 and RalA depletion inhibited cell migration to a similar extent. Stable lentivirus short hairpin interfering RNA-mediated depletion of RalA and RalBP1 in PC3 human prostate cancer cells inhibited bone metastasis after intracardiac inoculation. Depletion of RalBP1 diminished orthotopic tumor growth of PC3 cells and inhibited spontaneous metastasis from this site. Interestingly, the expression of wild-type or RalA mutants deficient in RalBP1 binding was effective at rescuing the reduced metastatic capacity of RalA-depleted PC3 cells, suggesting that RalA depletion does not reduce this solely by diminished interaction with RalBP1. To determine whether the role of RalBP1 in metastasis is relevant beyond prostate cancer, we studied the requirement of RalBP1 expression in an experimental metastasis model of human bladder cancer, a tumor type with high RalBP1 expression. Depletion of RalBP1 in UMUC3 cells resulted in decreased lung colonization while having a minimal effect on subcutaneous tumor growth. Our studies are the first to suggest that the expression of RalBP1 is necessary for human cancer cell metastasis. Furthermore, we show that the requirement for RalA expression for manifestation of this phenotype is not entirely dependent on a RalA-RalBP1 interaction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170262      PMCID: PMC3003135          DOI: 10.1593/neo.101080

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  24 in total

1.  RalA and RalB: antagonistic relatives in cancer cell migration.

Authors:  Gary Oxford; Charles R Owens; Brian J Titus; Tonia L Foreman; Mikael C Herlevsen; Steven C Smith; Dan Theodorescu
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

2.  Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.

Authors:  Y Wu; K McRoberts; S S Berr; H F Frierson; M Conaway; D Theodorescu
Journal:  Oncogene       Date:  2006-07-31       Impact factor: 9.867

3.  RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival.

Authors:  Yuchen Chien; Sungchan Kim; Ron Bumeister; Yueh-Ming Loo; Sung Won Kwon; Cynthia L Johnson; Mirey G Balakireva; Yves Romeo; Levy Kopelovich; Michael Gale; Charles Yeaman; Jacques H Camonis; Yingming Zhao; Michael A White
Journal:  Cell       Date:  2006-10-06       Impact factor: 41.582

4.  Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

Authors:  Kian-Huat Lim; Kevin O'Hayer; Stacey J Adam; S Disean Kendall; Paul M Campbell; Channing J Der; Christopher M Counter
Journal:  Curr Biol       Date:  2006-12-19       Impact factor: 10.834

5.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells.

Authors:  Kian-Huat Lim; Antonio T Baines; James J Fiordalisi; Michail Shipitsin; Larry A Feig; Adrienne D Cox; Channing J Der; Christopher M Counter
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

6.  Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).

Authors:  Sharad S Singhal; Jyotsana Singhal; Sushma Yadav; Seema Dwivedi; Paul J Boor; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

7.  Regression of melanoma in a murine model by RLIP76 depletion.

Authors:  Sharad S Singhal; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 8.  Ral GTPases and cancer: linchpin support of the tumorigenic platform.

Authors:  Brian O Bodemann; Michael A White
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

9.  Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.

Authors:  JuanJuan Yin; Claire Pollock; Kirsten Tracy; Monika Chock; Philip Martin; Michael Oberst; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

10.  Expression of ral GTPases, their effectors, and activators in human bladder cancer.

Authors:  Steven Christopher Smith; Gary Oxford; Alexander S Baras; Charles Owens; Dmytro Havaleshko; David L Brautigan; Martin K Safo; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

View more
  36 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

Review 3.  Ral GTPases in tumorigenesis: emerging from the shadows.

Authors:  David F Kashatus
Journal:  Exp Cell Res       Date:  2013-07-02       Impact factor: 3.905

4.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 5.  The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.

Authors:  Sunny Guin; Dan Theodorescu
Journal:  Acta Pharmacol Sin       Date:  2015-01-05       Impact factor: 6.150

Review 6.  RLIP76 Targeted Therapy for Kidney Cancer.

Authors:  Sharad S Singhal; Jyotsana Singhal; James Figarola; David Horne; Sanjay Awasthi
Journal:  Pharm Res       Date:  2015-05-29       Impact factor: 4.200

7.  Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse.

Authors:  Nathan M Mollberg; Gunnar Steinert; Maximillian Aigner; Alexander Hamm; Fang-Ju Lin; Heike Elbers; Christoph Reissfelder; Jürgen Weitz; Markus W Buchler; Moritz Koch
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

Review 8.  Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer.

Authors:  Sharad S Singhal; Divya Jain; Preeti Singhal; Sanjay Awasthi; Jyotsana Singhal; David Horne
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-28       Impact factor: 10.680

9.  CD24 is an effector of HIF-1-driven primary tumor growth and metastasis.

Authors:  Shibu Thomas; Michael A Harding; Steven C Smith; Jonathan B Overdevest; Matthew D Nitz; Henry F Frierson; Scott A Tomlins; Glen Kristiansen; Dan Theodorescu
Journal:  Cancer Res       Date:  2012-08-27       Impact factor: 12.701

Review 10.  Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame.

Authors:  Leanna R Gentry; Timothy D Martin; David J Reiner; Channing J Der
Journal:  Biochim Biophys Acta       Date:  2014-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.